Alzheimer's disease (AD) is a clinico-pathological entity combining multiple and varied neuropathological lesions with characteristic abnormal accumulations (amyloid Beta (Aβ) plaques and neurofibrillary degeneration (NFD)), neuroinflammation, as well as neuronal and synaptic suffering.
To date, only symptomatic treatments are available, with no proven effect on neuropathological lesions or on the clinical course of the disease.
Anti-TNF alpha could be a therapeutic agent of choice in the treatment of central nervous sytem (CNS) diseases with an inflammatory component, such as AD. Unfortunately, their high molecular weight prevents them from passively crossing the blood brain barrier (BBB). In a pilot study published in 2006, etanercept was administered intrathecally to AD patients with encouraging clinical effects.
Transient opening of the tight junctions between the endothelial cells of the BBB by delivering High Intensity Focalised Ultrasounds (HIFU) in combination with an intravenous injection of microbubbles is a strategy that could improve bioavailability. Studies suggest that the oscillation of microbubbles in the ultrasound field generates microcurrents that induce shear forces responsible for a transient opening of the BBB. Ultrasound can be focused or unfocused and open the BBB diffusely or selectively over defined regions of the brain. This technique was first used to open the BBB in humans in 2001.
Transient opening of the BBB is also thought to modulate the immune response in the CNS, leading to a reduction in the intracerebral load of Aβ. In an Alzheimer's mouse model, several studies using ultrasound devices to open the BBB have shown a reduction in the intracerebral load of Aβ (up to 75%) and an improvement in the memory faculties and cognitive performance of the animals.
In humans, two clinical trials have assessed the safety of using ultrasound-assisted BBB disruption devices in AD patients. These were the Sonocloud® (Carthera) and ExAblate® (InSightec) devices. The Sonocloud® device is an extra-dural ultrasound emitter implanted under local anaesthetic. Enrolment was completed in October 2020, but the results of the trial are not yet available (NCT03119961). The phase I study on 5 patients evaluating the ExAblate® device coupled with the injection of gas microbubbles demonstrated reversible opening of the BBB with no serious adverse effects for the patients. No effect on intracerebral Aβ load or cognitive or behavioural improvement was demonstrated. The ExAblate® device is not implantable and is therefore less invasive than the Sonocloud® device. However, it requires MRI monitoring and the transducers used often generate high levels of heat, requiring the use of a water cooling system to avoid the risk of transducer deterioration.
In this project, our aim is to assess the safety of using a non-focused ultrasound device, the General Electric VIVID S70 clinical device (CE mark G1 023782 0112 ), to perform BBB ruptures in patients suffering from AD, combined with the administration of etanercept, whose bioavailability would thus be improved.

Start Date01 Mar 2025

Sponsor / Collaborator

Fondation Ophtalmologique Adolphe de Rothschild

NCT06707194

/ Not yet recruitingPhase 4IIT

Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis: a Multicenter Randomized Controlled Clinical Study

The purpose of the study is to verify the clinical feasibility of Benzathine penicillin (BPG) /Etanercept (ETN) combination regimen in patients with spondyloarthritis (SpA) and at the same time compare Benzathine penicillin /Etanercept combination regimen and Etanercept maintenance therapy in reducing disease activity, improving patients' clinical symptoms and body function scores, enhancing quality of life, improving imaging performance and safety.

Start Date01 Mar 2025

Sponsor / Collaborator

Nanfang Hospital

NCT06654882

/ Not yet recruitingPhase 3IIT

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

Start Date01 Feb 2025

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with Etanercept

100 Translational Medicine associated with Etanercept

100 Patents (Medical) associated with Etanercept

9,462

Literatures (Medical) associated with Etanercept

01 Feb 2025·Rheumatology and Therapy

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis

Article

Author: Littlejohn, Geoffrey ; Butcher, Belinda ; Walsh, Nicole ; Tahir, Talib ; Calao, Miriam ; Ciciriello, Sabina ; Youssef, Peter ; Smith, Tegan ; O'Sullivan, Catherine ; Leadbetter, Joanna

INTRODUCTION:

This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA).

METHODS:

This retrospective, non-interventional study used the OPAL dataset, derived from electronic medical records. Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023. Median persistence (Kaplan-Meier) and effectiveness (Disease Activity Score 28-joint C-reactive protein, three variables [DAS28CRP{3}]) were evaluated for UPA-treated patients and in three propensity score-matched cohorts: UPA monotherapy versus combination therapy, UPA versus other JAKis, and UPA versus TNFis.

RESULTS:

In patients prescribed UPA, 41.3% were ≥ 65 years old, 33.8% were prescribed as first-line advanced therapy, and 27.2% were prescribed monotherapy. Persistence on UPA was 26.6 months (95% confidence intervals: 24.4, 29.9) and longest in earlier lines of therapy. The DAS28CRP(3) remission rate was 73% at 3 months, with improvements observed across lines of therapy. UPA monotherapy and combination therapy had similar persistence (27.8 [23.5, 33.4] versus 30.4 months [22.1, 35.3], p = 0.84) and effectiveness. UPA showed longer persistence than other JAKis (28.8 [25.6, 32.4] versus 17.2 months [14.9, 19.8], p < 0.001) and TNFis (26.6 [24.9, 30.8] versus 13.3 months [11.5, 14.5], p < 0.001). DAS28CRP(3) remission rates were greater at 3 months for UPA than other JAKis (75.0% versus 61.5%) and TNFis (72.7% versus 59.5%). In unmatched subgroups, compared to cycling between TNFis, switching to UPA from other JAKis or TNFis resulted in longer persistence (JAKi-to-UPA: 25.3 [16.1, not reached]; TNFi-to-UPA: 27.8 [23.2, 35.4]; TNFi-to-TNFi: 9.6 [8.4, 10.7]) and greater DAS28CRP(3) remission rates over 9 months.

CONCLUSIONS:

Overall, the breadth and depth of data from this large real-world dataset continue to support a favorable clinical profile of UPA for the treatment of RA and may inform treatment choices in everyday clinical practice.

01 Feb 2025·JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Peri-implantation treatment with TNF-α inhibitor for endometriosis and/or adenomyosis women undergoing frozen-thawed embryo transfer: A retrospective cohort study

Article

Author: Yin, Ping ; Yuan, Yuan ; Li, Yan ; Liu, Mengqi ; Jiang, Min ; Yang, Dongzi

PROBLEM:

Endometriosis and adenomyosis have common pathogenesis and close relationship, with multi-factors involved in related infertility and IVF failure. They lead to anatomical changes, ovarian reserve reduction, endocrine abnormalities, altered endometrial receptivity and immunological dysfunction. Collective evidence indicate that abnormal function of immune cells and secretion of cytokines are closely related to reproductive outcomes among the women. Some studies showed that increased secretion of tumor necrosis factor alpha (TNF-α) led a key role in pro-inflammatory response in women with endometriosis/adenomyosis.TNF-a is embrryotoxic and receptivity impairing. Therefore, immunotherapy is a targeted therapeutic strategy apart from routine treatment. TNF-α inhibitors such as etanercept and adalimumab were shown to reduce the embryotoxic and anti-inflammatory effects to increase IVF pregnancy rates in recurrent implantation failure or endometrioma patient. However, there's no evidence about the use of adalimumab for patients with endometriosis and/or adenomyosis undergoing Frozen embryo transfer(FET).

METHOD OF STUDY:

A retrospective analysis of 141 women with endometriosis and/or adenomyosis undergoing FET from January 2021 to Jun 2023 was conducted.They were 20-42 years old, with or without previous implantation failure. Endometriosis was diagnosed by laparoscopy during their infertility workup and adenomyosis was confirmed by vaginal ultrasound screening. GnRH agonist and hormone replacement treatment (HRT) or HRT were taken for endometrium preparation according to doctor's evaluation and preference. Before and after embryo transfer, 84 women were treated with Adalimumab and 57 patients were untreated. Implantation rate, clinical pregnancy rate, ongoing pregnancy rate and live birth rate were compared between the two groups.

RESULTS:

The demographics and baseline characteristics between the two groups were comparable. Stage of embryo transferred and number of embryo transferred were comparable between the two groups (p = 0.227 and p = 0.204 separately). The regimen of endometrium preparation was similar too(p = 0.907). The implantation rate was significantly improved in study group (28.09 % vs 49.18 %, X²=9.515, P = 0.002). The clinical pregnancy rate was much lower in control group comparing with TNF-α inhibitor treatment group (42.11 % vs 60.71 %, X²=4.723, P = 0.029). There was no significant difference between the two groups as for ongoing pregnancy rate (38.60 % vs 52.38 %, X²=2.591, P = 0.107)and live birth rate (36.84 % vs 47.62 %, X²=1.606, P = 0.205). Following adjustment for age, BMI, number of prior failed transfer, stage of embryo transferred in a multiple logistic analysis, patients treated without TNF-α inhibitor had a significant lower CPR (ORadj 0.45, 95 %CI 0.22-0.92, p = 0.029) and a similar probability for OPR (ORadj 0.56, 95 %CI 0.28-1.12) and LBR (ORadj 0.62, 95 %CI 0.31-1.26) as compared with patients with TNF-α inhibitor treatment. However, an obvious trend of improvement of LBR was observed and it's clinical relevant for the patients.

CONCLUSION:

In women with endometriosis and/or adenomyosis, peri-implantation treatment with TNF-α inhibitor increased implantation rate and clinical pregnancy rate significantly compared with control group in FET cycles. The ongoing pregnancy rate and live birth rate were not significant different, while the difference was clinical relevant.

01 Jan 2025·JOINT BONE SPINE

Dacryoadenitis occurring during treatment with etanercept

Letter

Author: Bahiri, Rachid ; Amine, Bouchra ; Zemrani, Salma ; Rostom, Samira ; Elbinoune, Imane

156

News (Medical) associated with Etanercept

12 Dec 2024

·www.globenewswire.com

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). “We are excited to welcome Eric Benevich to the Board of Directors,” said Timothy P. Coughlin, Chairman of the Board of aTyr. “His extensive background bringing new products to market and the knowledge and expertise he has gained from both building and leading commercial activities at biopharmaceutical companies will be an invaluable resource as aTyr continues its evolution towards commercialization.” Mr. Benevich has served as Chief Commercial Officer of Neurocrine since May 2015 and is responsible for all aspects of commercial development, marketing, and sales of the Neurocrine product portfolio. Mr. Benevich has over 30 years of commercial experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals in the sales and marketing of drugs such as Prilosec®, Epogen®, Enbrel®, and Neudexta®. Mr. Benevich has a BBA in International Business from Washington State University. About aTyr aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential benefits that Mr. Benevich’s appointment will have on aTyr’s evolution towards commercialization. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contact:Ashlee DunstonDirector, Investor Relations and Corporate Communicationsadunston@atyrpharma.com

Executive Change

11 Nov 2024

·www.globenewswire.com

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® and Spinraza®. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers. “I am thrilled to welcome Dr. Doug Williams to Climb Bio. As our incoming Chair of the Board, Doug’s experiences over his 30 plus year career building and leading a range of biotechnology and pharmaceutical companies will offer critical perspective as we grow Climb Bio,” said Aoife Brennan, President and CEO of Climb Bio. “In particular, Doug’s expertise in immunology drug development will be very valuable as we pursue our mission to develop better treatments for the approximately 50 million patients in the U.S. and many more globally living with immune-mediated diseases.” Dr. Williams previously served as the President of Research and Development at Sana Biotechnology and was CEO of Codiak BioSciences. He has also served as Executive Vice President of Research and Development at Biogen. Prior to Biogen he was CEO at ZymoGenetics and led its acquisition by Bristol Myers Squibb. He has also held a variety of leadership positions, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics (acquired by Pfizer in 2023), Senior Vice President and Washington Site Leader at Amgen and Executive Vice President and Chief Technology Officer and a member of the Board of Directors at Immunex (acquired by Amgen in 2021). Dr. Williams has served as a board member of more than a dozen public and private biotechnology companies and is currently Chair of the Board of AC Immune SA and a Director of Stablix. He holds a Ph.D. from the State University of New York at Buffalo, Roswell Park Division and completed a postdoctoral fellowship at Indiana University School of Medicine. Dr. Williams added: “I am honored to be joining Climb Bio’s Board at this exciting time as they work to advance budoprutug and build a leading immune-mediated disease focused company. I believe budoprutug has potential across a broad range of B-cell mediated diseases and provides a cornerstone for the company to expand. I look forward to working with the talented Climb Bio team and the board to help them advance their mission to develop therapeutics for patients with immune-mediated diseases.” “I look forward to continuing to work with Aoife, the Climb Bio team, and other board members,” stated Andrew Levin, a member of Climb Bio’s Board and former Chair of the Board. “In the short time since acquiring Tenet Medicines, we have achieved a great deal. With the tremendous opportunity ahead, I am excited to transition the Chair role to Doug while remaining on the Board. Doug has incredible experience and a proven track record in building successful biotechnology companies and will be invaluable in guiding Climb Bio going forward. In addition, on behalf of the Board, I would also like to thank Liam for his valuable contributions and commitment to the Company through its transition.” About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; the anticipated benefits of the acquisition of Tenet Medicines, Inc.; expectations regarding budoprutug’s therapeutic benefits, clinical potential and clinical development; plans to optimize the administration of budoprutug; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc.; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio’s ability to advance budoprutug on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials of budoprutug; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. InvestorsChris Brinzey ICR Healthcarechris.brinzey@icrhealthcare.com 339-970-2843 MediaJon YuICR Healthcarejon.yu@icrhealthcare.com475-395-5375

Executive ChangeAcquisition

31 Oct 2024

·www.biospace.com

Amgen Whets Investors’ Appetites for MariTide Obesity Data by End of Year

iStock, hapabapa While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on the highly anticipated MariTide Phase II results slated for late 2024, according to BMO Capital Markets analyst Evan Seigerman. Amgen released its third-quarter earnings report on Wednesday, revealing an overall solid performance in Q3 despite misses by some of its key products. The company’s revenues in the quarter came in at $8.5 billion, representing 23% year-over-year growth. Amgen’s total revenues were broadly in line—if not slightly behind—the consensus estimate of $8.51 billion. Non-GAAP earnings-per-share (EPS) was $5.58, which beat the analyst forecasted figure of $5.13. Amgen CEO Robert Bradway in an investor call credited its strong Q3 performance on 10 products, which delivered “double-digit or better sales growth.” Among its key growth drivers was the acute lymphoblastic leukemia therapy Blincyto, which surged 49% year-over-year to bring in $327 million in the quarter, and beating the consensus estimate by 19%. Meanwhile, Repatha saw a 40% jump in sales compared to the same period last year. The hyperlipidemia medicine brought in $567 million in Q3, coming 6% ahead of analyst expectations. The oral non-small cell lung cancer pill Lumakras also had strong growth in the quarter, jumping 88% year-over-year to hit global sales of $98 million. Lumakras beat the Wall Street consensus, surpassing projections by 18%. By contrast, Amgen’s top-selling assets Tepezza and Prolia had a largely disappointing Q3, with the thyroid eye disease therapy generating $488 million in the quarter—missing the consensus expectation by 4%-- while the osteoporosis injection secured nearly $1.05 billion, 6% lower than analysts’ forecast. Sales of the autoimmune medication Enbrel dropped 20% in the quarter with revenues of $825 million, which also fell 10% short of the consensus. BMO Capital Markets analyst Evan Seigerman in an investor note called Wednesday’s results “somewhat uneventful,” marked by “limited details” for the Amgen’s highly anticipated obesity candidate MariTide. Executives on the investor call only revealed that the MariTide Phase II study is “progressing well” and that they are currently planning to “launch a broad Phase III program” for the candidate, targeting obesity and related conditions as well as type 2 diabetes. Data from MariTide’s Phase II study are expected “later this year,” according to Bradway. After the call, Mizuho analyst Salim Syed in an investor note said that there was “not much new learned” about the the company’s obesity portfolio, pointing out that Amgen provided only “incremental points” regarding its development plans in this space. “Management again alluded to a ‘differentiated profile,’ but no additional [details] of substance were really provided,” even in the Q&A portion of the call, according to Syed. For Jefferies analyst Michael Yee, a lot is riding on Amgen’s impending MariTide readout. Yee called the company’s Q3 results “ho-hum” but noted that investors are willing to “look past this … if the obesity data is good.” The focus for MariTide, according to Yee, is on its “long-term blockbuster potential.” However, “if data is messy, investors will be more frustrated,” given that Amgen’s business will be “under some pressure” in 2025, including the impending entry of Prolia biosimilars, Yee wrote.

Phase 2Financial Statement

100 Deals associated with Etanercept

External Link

KEGG	Wiki	ATC	Drug Bank
D00742	Etanercept	L04AB01	DB00005

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Psoriasis	CN	C.H. Boehringer Sohn AG & Co. KG	26 Feb 2010
Non-radiographic axial spondyloarthritis	AU	Pfizer Australia Pty Ltd.	18 Mar 2003
Polyarticular Juvenile Idiopathic Arthritis	US	Immunex Corp.	15 Jan 2002
Ankylosing Spondylitis	EU	Pfizer Europe MA EEIG	02 Feb 2000
Ankylosing Spondylitis	IS	Pfizer Europe MA EEIG	02 Feb 2000
Ankylosing Spondylitis	LI	Pfizer Europe MA EEIG	02 Feb 2000
Ankylosing Spondylitis	NO	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	EU	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	IS	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	LI	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	NO	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	EU	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	IS	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	LI	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	NO	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	EU	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	IS	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	LI	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	NO	Pfizer Europe MA EEIG	02 Feb 2000
Juvenile Idiopathic Arthritis	EU	Pfizer Europe MA EEIG	02 Feb 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	US	Amgen, Inc.	29 Nov 2016
Pain	Phase 3	PR	Amgen, Inc.	29 Nov 2016
Juvenile Pauciarticular Chronic Arthritis	Phase 3	AU	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	BE	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	CO	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	CZ	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	FR	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	DE	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	HU	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	IT	Pfizer Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Rituximab	mmwubmubec(svxntrtufn) = gqybyqcucy yqsgjzhcfi (ngptegdsou ) View more	-	05 Jun 2024
				Tocilizumab	mmwubmubec(svxntrtufn) = bulkxxnsay yqsgjzhcfi (ngptegdsou ) View more
EULAR2024	Not Applicable	Juvenile Idiopathic Arthritis First line	118	Etanercept (ETN)	konzypgxnl(gcpvnicqpb) = ogpilrkpnx nqrywwcmjs (lugvbkwqex )	Positive	05 Jun 2024
				Adalimumab (ADA)	konzypgxnl(gcpvnicqpb) = bhihqpubzw nqrywwcmjs (lugvbkwqex )
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	biologic drugs (Obese patients)	otvmpawkdh(mbymnwygkj) = kugwwizqij kkocfldlkn (iurqetfqqe ) View more	Negative	05 Jun 2024
				biologic drugs (Non-obese patients)	otvmpawkdh(mbymnwygkj) = lpwaufksle kkocfldlkn (iurqetfqqe ) View more
EULAR2024	Not Applicable	-	-	Etanercept bio-originator	grvetsofzp(awknvmvpus) = 28% vs 22%, mostly injection site reactions kqmtycbuau (myrpiixjhn ) View more	-	05 Jun 2024
				Etanercept biosimilar SB4
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	golpufubsl(kzxhhdghnn) = vushdhoeei yewqgbcxzl (tkfjigrenp )	Positive	05 Jun 2024
				Infliximab (IFX)	golpufubsl(kzxhhdghnn) = drsqundigm yewqgbcxzl (tkfjigrenp )
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Biologic and targeted synthetic DMARDs	xweqnyxndc(ulyqfdxkxb) = xygijjfdlh sxvfemeztn (rvvytdpwzh ) View more	-	05 Jun 2024
NCT02464878 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	2	Islet Transplantation+Thymoglobulin+Basiliximab+Alpha 1-Antitrypsin+Etanercept	jmqbrwzphy(nopwphoufn) = tmrhttdxgv kqzizbfbzf (icsdvulcza, pcajkkjrww - euvutfukem) View more	-	22 Dec 2023
ACR2023	Not Applicable	Spondylarthritis	-	Etanercept	bqnxaptwjy(kujnzcfqgu) = zdnmusajmt lkfzcprryj (hkdvcdzxdt, 1.2 - 7.0)	Positive	14 Nov 2023
				Anti-TNF	bqnxaptwjy(kujnzcfqgu) = asecimbrmy lkfzcprryj (hkdvcdzxdt, 0.4 - 1.8)
NCT03636373 (CTgov)	Phase 4	Primary gout	5	Etanercept (Etanercept)	lwjtamikfc(lwmrklpsxs) = yrqfolzauq bjaqxawsud (bcudkkxjyg, fhdgzgmzqi - dwpvrawepp) View more	-	27 Oct 2023
				Triamcinolone Acetonide (Triamcinolone Acetonide)	lwjtamikfc(lwmrklpsxs) = rsqtbyucpm bjaqxawsud (bcudkkxjyg, qvlyyhxyks - hvxkuzlahd) View more
FDA Manual	Not Applicable	Plaque psoriasis	211	Placebo	zorikokezo(wjyxjjhqdf) = ydxthhzvps awznwzrfet (hwpsihckog ) View more	Positive	18 Oct 2023
				Enbrel 0.8 mg/kg	zorikokezo(wjyxjjhqdf) = uvyeigqhkj awznwzrfet (hwpsihckog ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis